HeMo Bioengineering this week announced that it received pre-market approval in China for its aspiration catheter.
The Afentta intracranial thrombectomy aspiration catheter is a direct aspiration treatment option for acute ischemic stroke thrombectomy and has demonstrated lower post-stroke treatment disability rates and disease burden in clinical studies, according to the company.
“Afentta has demonstrated shorter procedure times, higher recanalization rates, lower disability rates and lower incidence of arterial dissection, presenting a more efficacious, faster and safer treatment option in interventional thrombectomy,” Miao Zhongrong, head of the department of interventional neuroradiology at Beijing Tiantan Hospital, said in a news release.
Afentta is the first intracranial thrombectomy aspiration catheter that has received approval from the National Medical Products Administration.
“HeMo Bioengineering is committed to bringing together ‘smart’ resources to serve China’s needs in the neurovascular interventional space. With our professional management team of industry veterans and our diversified and global research and education resources, we are well-positioned to continue delivering world-leading, reliable and innovative medical devices,” founder and chief technology officer Jack Wang said.
